These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 15569999

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR.
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [Abstract] [Full Text] [Related]

  • 5. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
    Loomis R, Carbone R, Reiss M, Lacy J.
    Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
    [Abstract] [Full Text] [Related]

  • 6. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 7. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
    Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC.
    Clin Cancer Res; 2003 Jul; 9(7):2826-36. PubMed ID: 12855663
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.
    Loriot Y, Mordant P, Brown BD, Bourhis J, Soria JC, Deutsch E.
    Anticancer Res; 2010 Oct; 30(10):3869-78. PubMed ID: 21036697
    [Abstract] [Full Text] [Related]

  • 9. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K.
    Clin Cancer Res; 2003 Sep 15; 9(11):4267-73. PubMed ID: 14519654
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD.
    Oncology (Williston Park); 2004 Nov 15; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [Abstract] [Full Text] [Related]

  • 12. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
    Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4185-91. PubMed ID: 15217956
    [Abstract] [Full Text] [Related]

  • 13. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
    Robinson LA, Smith LJ, Fontaine MP, Kay HD, Mountjoy CP, Pirruccello SJ.
    Ann Thorac Surg; 1995 Dec 15; 60(6):1583-91. PubMed ID: 8787447
    [Abstract] [Full Text] [Related]

  • 14. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.
    Oncol Rep; 2008 Sep 15; 20(3):581-7. PubMed ID: 18695909
    [Abstract] [Full Text] [Related]

  • 15. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK.
    Clin Cancer Res; 2004 Aug 01; 10(15):5048-57. PubMed ID: 15297406
    [Abstract] [Full Text] [Related]

  • 16. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A.
    Clin Cancer Res; 2006 May 01; 12(9):2902-11. PubMed ID: 16675587
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
    Geiger T, Müller M, Monia BP, Fabbro D.
    Clin Cancer Res; 1997 Jul 01; 3(7):1179-85. PubMed ID: 9815797
    [Abstract] [Full Text] [Related]

  • 18. Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.
    De Cesare M, Perego P, Righetti SC, Pratesi G, Carenini N, Rivoltini L, Zupi G, Del Bufalo D, Balsari A, Zunino F.
    Eur J Cancer; 2005 May 01; 41(8):1213-22. PubMed ID: 15911246
    [Abstract] [Full Text] [Related]

  • 19. Oblimersen in the treatment of metastatic melanoma.
    Tarhini AA, Kirkwood JM.
    Future Oncol; 2007 Jun 01; 3(3):263-71. PubMed ID: 17547520
    [Abstract] [Full Text] [Related]

  • 20. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A.
    Clin Cancer Res; 2002 Apr 01; 8(4):1277-83. PubMed ID: 11948143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.